Aim: The aim of this study was to determine the proportion of cystic tumors according to preoperative CT (Bosniak III, IV) among surgically treated patients with histologically confirmed papillary renal cell carcinoma (pRCC) and to assess progression rates among patients with and without cystic appearance on imaging. Methods: A total of 138 patients with pRCC histology surgically treated in the period of January 2007–March 2017 were included. Clinical and radiological characteristics, type of surgery, histopathology results, and follow-up data were recorded and statistically evaluated. Results: Forty-one cases (29.7%) of cystic lesions (10× BIIF, 14× BIII, 17× BIV) were detected by CT. Patients with pRCC1 significantly more frequently presented with cystic appearance on CT (33/78; 42.3%) in comparison to other papillary types (8/60; 13.3%; p = 0.0002). During a median follow-up time of 49.4 months, only 2 patients with cystic lesions progressed after surgery. Conclusions: Cystic appearance on imaging methods is mainly a characteristic of pRCC1 (42.3%). Cystic morphology on imaging might predict a relatively indolent behavior of all pRCC types. Preoperative scoring systems including tumor growth patterns (cystic vs. solid) are needed for further classification.

Keywords:
Bosniak, Cystic, Grade, Papillary, Prognosis, Solid
1.
Saleeb RM, Brimo F, Farag M, Rompré-Brodeur Rotondo F, Beharry V, Wala Plant P, Downes MR, Pace K, Evans Bjarnason G, Bartlett JMS, Yousef GM: Toward biological subtyping of papillary renal cell carcinoma with clinical implications through histologic, immunohistochemical, and molecular analysis. Am J Surg Pathol 2017; 41: 1618–1629.
2.
Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, et al.: Comprehensive molecular characterization of papillary renal cell-carcinoma. N Engl J Med 2016; 374: 135–145.
3.
Peckova K, Martinek P, Pivovarcikova K, Vanecek T, Alaghehbandan R, Prochazkova K, et al: Cystic and necrotic papillary renal cell carcinoma: prognosis, morphology, immunohistochemical, and molecular-genetic profile of 10 cases. Ann Diagn Pathol 2017; 26: 23–30.
4.
Procházková K, Staehler M, Travníček I, et al: Morphological characterization of papillary renal cell carcinoma type 1, the efficiency of its surgical treatment. Urol Inter 2017; 98: 148–155.
5.
Pivovarcikova K, Peckova K, Martinek P, Montiel DP, Kalusova K, Pitra T, et al: “Mucin”-secreting papillary renal cell carcinoma: clinicopathological, immunohistochemical, and molecular genetic analysis of seven cases. Virchows Arch 2016; 469: 71–80.
6.
Pitra T, Pivovarcikova K, Alaghehbandan R, Hes O: Chromosomal numerical aberration pattern in papillary renal cell carcinoma: Review article. Ann Diagn Pathol 2017;pii: S1092-9134(17)30318-0.
7.
Lefèvre M, Couturier J, Sibony M, Bazille C, Boyer K, Callard P, Vieillefond A, Allory Y: Adult papillary renal tumor with oncocytic cells: clinicopathologic, immunohistochemical, and cytogenetic features of 10 cases. Am J Surg Pathol 2005; 29: 1576–1581.
8.
Hes O, Brunelli M, Michal M, Cossu Rocca P, Hora M, Chilosi M, et al: Oncocytic papillary renal cell carcinoma: a clinicopathologic, immunohistochemical, ultrastructural, and interphase cytogenetic study of 12 cases. Ann Diagn Pathol 2006; 10: 133–139.
9.
Ürge T, Hes O, Ferda J, Chudá?ek Z, Eret V, Michal M, et al: Typical signs of oncocytic papillary renal cell carcinoma in everyday clinical praxis. World J Urol 2010; 28: 513–517.
10.
Kuroda N, Kanomata N, Yamaguchi T, Imamura Y, Ohe C, Sakaida N, et al: Immunohistochemical application of S100A1 in renal oncocytoma, oncocytic papillary renal cell carcinoma, and two variants of chromophobe renal cell carcinoma. Med Mol Morphol 2011; 44: 111–115.
11.
Hes O, Brunelli M, Hora M, Michal M: A novel oncocytoid papillary renal cell carcinoma, type 2, with aberrant cytogenetic abnormalities: oncocytic papillary renal cell carcinoma? Pathology 2013; 45: 441.
12.
Moch H, Humphrey PH, Ulbright TM, Reuter VE (Eds): WHO Classification of Tumours of the Urinary System and Male Genital Organs (ed 4). IARC, 2016, pp 356.
13.
Weibl P, Hora M, Kollarik B, Shariat S, Klatte T: Management, pathology and outcomes of Bosniak category IIF and III cystic renal lesions. World J Urol 2015; 33: 295–300.
14.
Donin NM, Mohan S, Pham H, Chandarana H, Doshi A, Deng FM, et al: Clinicopathologic outcomes of cystic renal cell carcinoma. Am J Roentgenol 2013; 201: 347–355.
15.
Smith AD, Allen BC, Sanyal R, Carson JD, Zhang H, Williams JH, et al: Outcomes and complications related to the management of Bosniak cystic renal lesions. Am J Roentgenol 2015; 204:W550–W556.
16.
Kutikov A, Uzzo RG: The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 2015; 182: 844–853.
17.
Vikram R, Ng CS, Tamboli P, Tannir NM, Jonasch E, Matin SF, et al: Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. RadioGraphics 2009; 29: 741–754.
18.
Oh TH, Seo IY: The role of Bosniak classification in malignant tumor diagnosis: a single institution experience. Investig Clin Urol 2016; 57: 100–105.
19.
Bosniak MA: The Bosniak renal cyst classification: 25 years later. Radiology 2012; 262: 781–785.
20.
Shin T, Duddalwar VA, Ukimura O, Matsugasumi T, Chen F, Ahmadi N, et al: Does computed tomography still have limitations to distinguish benign from malignant renal tumors for radiologists? Urol Int 2017; 99: 229–236.
21.
Reese AC, Johnson PT, Gorin MA, Pierorazio PM, Allaf ME, Fishman EK, et al: Pathological characteristics and radiographic correlates of complex renal cysts. Urol Oncol 2014; 32: 1010–1016.
22.
Egbert ND, Caoili EM, Cohan RH, Davenport MS, Francis IR, Kunju LP, et al: Differentiation of papillary renal cell carcinoma subtypes on CT and MRI. Am J Roentgenol 2013; 201: 347–355.
23.
Mirka H, Korcakova E, Kastner J, Hora M, Hes O, Hosek P, et al: Diffusion-weighted imaging using 3.0 T MRI as a possible biomarker of renal tumors. Anticancer Res 2015; 35: 2351–2357.
24.
Pitra T, Pivovarcikova K, Tupy R, et al: Magnetic resonance imaging as an adjunct diagnostic tool in computed tomography defined Bosniak IIF-III renal cysts: a multicenter study. World J Urol 2018; 36: 905–911.
25.
Huber J, Winkler A, Jakobi H, Bruckner T, Roth W, Hallscheidt P, et al: Preoperative decision making for renal cell carcinoma: cystic morphology in cross-sectional imaging might predict lower malignant potential. Urol Oncol 2014; 32: 37:e1–e6.
26.
Brinker DA, Amin MB, de Peralta-Venturina M, Reuter V, Chan DY, Epstein JI: Extensively necrotic cystic renal cell carcinoma: a clinicopathologic study with comparison to other cystic and necrotic renal cancers. Am J Surg Pathol 2000; 24: 988–995.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.